Recombinant H7 Hemagglutinin Influenza Vaccine Trial

Summary

Recombinant H7 (rH7) vaccine has been shown to be poorly immunogenic in previous human clinical trials. This study will test approaches to improve the immunogenicity of H7 vaccine, namely use of a three dose regimen, use of a modified H7 HA sequence from which the Tregitope has been removed (rH7m), and inclusion of delta inulin adjuvant adjuvant in the vaccine

Timeline

Start

2017-01

Primary completion

2017-11

Completion

2019-05

Drugs

Indications